{"id":"f-18-fludeoxyglucose","safety":{"commonSideEffects":[{"rate":null,"effect":"Radiation exposure"},{"rate":null,"effect":"Hypoglycemia (rare, from glucose load)"}]},"_chembl":null,"_dailymed":{"setId":"5d05df4a-463e-4e66-9387-f3a842e20cd0","title":"FLUDEOXYGLUCOSE F 18 (FLUDEOXYGLUCOSE F-18) INJECTION, SOLUTION [JUBILANT DRAXIMAGE INC., DBA JUBILANT RADIOPHARMA]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of fluorodeoxyglucose (FDG), a glucose molecule with a fluorine-18 radioisotope attached. Cancer cells and other metabolically active tissues consume glucose at higher rates than normal tissue, causing FDG to preferentially accumulate in these areas. The fluorine-18 emits positrons that are detected by PET scanners, producing images that reveal areas of abnormal metabolism.","oneSentence":"[F-18]-Fludeoxyglucose is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues, enabling visualization of glucose uptake via positron emission tomography (PET) imaging.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:32:45.657Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma)"},{"name":"Neurology: evaluation of dementia and neurodegenerative disorders"},{"name":"Cardiology: assessment of myocardial viability in coronary artery disease"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ASPARTATE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"BLOOD LACTATE DEHYDROGENASE INCREASED"},{"count":1,"reaction":"CHEST PAIN"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":1,"reaction":"LYMPHOCYTE PERCENTAGE DECREASED"},{"count":1,"reaction":"MULTI-ORGAN FAILURE"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"SEPTIC SHOCK"}],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["FDG","Fluorodeoxyglucose","F-18-FDG"],"phase":"marketed","status":"active","brandName":"[F-18]-Fludeoxyglucose","genericName":"[F-18]-Fludeoxyglucose","companyName":"University of Saskatchewan","companyId":"university-of-saskatchewan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"[F-18]-Fludeoxyglucose is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues, enabling visualization of glucose uptake via positron emission tomography (PET) imaging. Used for Oncology: detection and staging of various cancers (lung, breast, colorectal, lymphoma, melanoma), Neurology: evaluation of dementia and neurodegenerative disorders, Cardiology: assessment of myocardial viability in coronary artery disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}